Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.

Kosuke SatoJun InoueTakehiro AkahaneTomoo KobayashiShuichi SatoNorihiro KisaraMasashi NinomiyaTomoaki IwataAkitoshi SanoMio TsuruokaMasazumi OnukiAtsushi Masamune

Published in: Medicine (2022)

The efficacy and safety were comparable in the TAF-switching group and the ETV-continuing group. Because the present study was conducted in limited patients, a larger study will be required.

Keyphrases

end stage renal disease
double blind
acute lymphoblastic leukemia
prognostic factors
open label
peritoneal dialysis
bone marrow
phase iii
placebo controlled
cell therapy
replacement therapy